contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


thor-medical-asa-invitation-to-presentation-of-second-half-and-full-year-2025-results

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Thor Medical är en producent och leverantör av alfapartikelemitterare för cancerbehandling. Radionuklidterapi (RNT) eller radioligandterapi (RLT) som använder alfapartikelemitterare är en lovande teknik för cancerbehandling. Huvudfokus för bolaget är att förfina produktionstekniken, säkra kundbasen och nödvändiga myndighetsgodkännanden för industrialisering. Thor Medical har sitt huvudkontor i Oslo.

Thor Medical

18.2.2026 07:00:00 CET | Thor Medical ASA | Non-regulatory press releases Thor Medical ASA will publish its second-half and full-year 2025 results on Thursday, February 26, 2026, at 07:00 CET...

<pre>18.2.2026 07:00:00 CET | Thor Medical ASA | Non-regulatory press releases Thor Medical ASA will publish its second-half and full-year 2025 results on Thursday, February 26, 2026, at 07:00 CET. The company will host a presentation of the results at 08:00 CET the same day at Sjølyst Møtesenter, Drammensveien 165, Oslo. Investors, analysts and media are invited to attend. Date: Thursday, February 26, 2026 Time: 08:00 CET Venue: Sjølyst Møtesenter, Drammensveien 165, Oslo Webcast: https://qcnl.tv/p/oaKSlZtoFMGAjpGTZIKcdg - https://nor01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fqcnl.tv%2Fp%2F oaKSlZtoFMGAjpGTZIKcdg&amp;data=05%7C02%7C%7C49a6bd5b0d794cb377a508de6d35f2a7%7C18d5 60945f654afda565a84b07f106b0%7C0%7C0%7C639068275629967674%7CUnknown%7CTWFpbGZsb3 d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIl dUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=gUG3dfimV2zYzWSKJrOMryzhJUeZE17BHqoelQNqYs4%3D &amp;reserved=0 The interim financial report for the second half and full year of 2025, and presentation material, will be released at 07:00 CET and made available on www.thormedical.com - http://www.thormedical.com CONTACTS Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, Thor Medical ASA, +47 988 05 724, mathias.reierth@thormedical.com ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit www.thormedical.com - http://www.thormedical.com. ATTACHMENTS Download announcement as PDF.pdf - https://kommunikasjon.ntb.no/ir-files/17848634/18808516/6798/Download%20announce ment%20as%20PDF.pdf </pre>

Thor Medical ASA: Invitation to Presentation of Second-Half and Full-Year 2025 Results